Intellectual Property

LMG Life Sciences Americas Awards (2025)

LMG Life Sciences Americas Awards (2025)

Managing IP Americas Awards (2025)

LSPN Awards USA (2026)

LSPN Awards USA (2026)

LMG Life Sciences Americas Awards (2026)

LSPN Awards USA (2025)

Managing IP (2025)

IAM Patent 1000 (2025)

IAM Patent 1000 (2025)

Successfully brought IPR challenges against two of Moderna’s patents on behalf of BioNTech and secured a stay of a federal district court litigation — effectively stopping Moderna’s case in its tracks.

Secured summary judgment of noninfringement on behalf of bluebird bio and Third Rock Ventures in a federal Delaware patent infringement action brought by San Rocco Therapeutics (SRT) stemming from a previously settled dispute relating to viral vectors used in gene therapies, including bluebird’s then-recently approved Zynteglo and Lyfgenia products. This followed on the heels of an early dismissal of a complex trade secrets dispute filed by SRT against bluebird bio, Third Rock Ventures, 2seventy bio and multiple individual defendants in Massachusetts federal court alleging multiple RICO violations premised on alleged trade secrets theft, mail and wire fraud, as well as alleged violations of federal and state antitrust laws.

Secured a complete victory on behalf of Chevron in a patent infringement lawsuit initiated by Pilot Energy Solutions in the Southern District of Texas alleging that Pilot Energy Solutions’ patented technology had huge commercial success, earning it hundreds of millions of dollars from natural gas recovery and that Chevron had made fraudulent misrepresentations to Pilot in order to cover up Chevron’s alleged infringing activity, ultimately securing the dismissal of Pilot’s misrepresentation claims with prejudice.

Successfully defeated a motion for a temporary restraining order and preliminary injunction on behalf of Inpria and JSR brought by The Research Foundation for the State University of New York threatening Inpria’s very existence by seeking to enjoin its use of dozens of patents and potentially precluding a planned acquisition of JSR (Inpria’s parent) in a $6.4 billion transaction by Japan Investment Corporation, a Japanese government-backed fund whose investments are overseen by the Japanese Ministry of Economy, Trade, and Industry.

Secured a ruling on behalf of L’Oréal USA that wiped out an infringement theory for all 130 L’Oréal USA products accused of infringement by the University of Massachusetts relating to patents covering methods of using adenosine.

Successfully conducted the first-ever Zoom Hatch-Waxman trial in the District of New Jersey where all challenges to patents protecting client Mitsubishi Tanabe’s blockbuster Invokana diabetes medication were rejected.

Secured a precedent-setting win and a seven-year exclusion order from the ITC for Viking Therapeutics against Ascletis in a first-of-its-kind, bet-the-company Section 337 ITC investigation and District Court litigation against Chinese entities accused of misappropriating hundreds of trade secrets and breaching a contract based on theft of proprietary information involving pharmaceutical formulations and clinical/preclinical information relating to non-alcoholic steatohepatitis treatments, earning the Paul Hastings team the “Litigator of the Week” distinction by The American Lawyer’s Litigation Daily.